18F-PI-2620 PET 在阿尔茨海默病及其他神经退行性疾病中显像 tau 蛋白的临床评估:与 18F-THK-5351 对比
本研究纳入 26 例轻度认知障碍、 probable AD、额颞叶痴呆或帕金森综合征患者及健康对照,注射 7 mCi(259 MBq)18F-PI-2620 后行 60–90 分钟脑 PET 扫描,部分受试者曾行 18F-THK-5351 或 18F-FP-CIT PET。结果显示 18F-PI-2620 在基底节无明显脱靶结合,Aβ+ 轻度认知障碍或 AD 患者额颞顶皮层摄取多样且与 MMSE 相关(ρ=-0.692,P=0.013),Aβ+ 帕金森病痴呆及原发进行性失语患者亦见额颞顶皮层摄取增高,帕金森综合征患者苍白球摄取较 Aβ- 健康对照增高。结论认为 18F-PI-2620 PET 可能是有助于检测 Aβ+ AD 及 Aβ+ 非 AD tau 蛋白病皮层 tau 沉积的敏感工具。
要点
- 18F-PI-2620 在基底节无明显脱靶结合,克服第一代 tau PET 示踪剂局限。
- Aβ+ 轻度认知障碍或 AD 患者额颞顶皮层摄取与 MMSE 相关(ρ=-0.692,P=0.013)。
- 帕金森综合征患者苍白球 18F-PI-2620 摄取较 Aβ- 健康对照增高。
核心结论
- 18F-PI-2620 PET 可能是有助于检测 Aβ+ AD 及 Aβ+ 非 AD tau 蛋白病皮层 tau 沉积的敏感工具。
- 18F-PI-2620 在基底节的脱靶结合不影响显像判读。
研究设计与样本
- 研究纳入 26 例诊断为轻度认知障碍、 probable AD、额颞叶痴呆或帕金森综合征的患者及健康对照。
- 所有受试者注射 7 mCi(259 MBq)18F-PI-2620 后行 60–90 分钟脑 PET 扫描。
- 部分受试者曾行 18F-THK-5351 或 18F-FP-CIT 多巴胺转运体 PET 显像。
主要发现
- 所有受试者 18F-PI-2620 PET 图像基底节脱靶结合未见增高。
- Aβ+ 轻度认知障碍或 AD 患者额颞顶皮层 18F-PI-2620 摄取多样,且与 MMSE 评分相关(ρ=-0.692,P=0.013)。
- Aβ+ 帕金森病痴呆及 Aβ 未知的原发进行性失语患者额颞顶皮层 18F-PI-2620 摄取亦增高。
- 帕金森综合征患者苍白球 18F-PI-2620 摄取较 Aβ- 健康对照增高(左侧:1.41 ± 0.14 vs 1.04 ± 0.13,P=0.014;右侧:1.18 ± 0.16 vs 0.95 ± 0.07,P=0.014)。
临床怎么用
- 18F-PI-2620 PET 可用于评估 Aβ+ AD 及 Aβ+ 非 AD tau 蛋白病患者的皮层 tau 沉积。
- 基底节脱靶结合不明显,有助于减少第一代 tau PET 示踪剂判读干扰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PET is a useful tool for detecting the presence and extent of brain tau accumulation. However, most first-generation tau PET tracers are limited for high off-target binding and detection of tau in non-Alzheimer disease (AD). This study evaluated potential clinical applications of F-PI-2620 as a novel PET tracer with a high binding affinity for tau deposition in AD and non-AD tauopathies. METHODS: Twenty-six participants diagnosed with either mild cognitive impairment, probable AD, frontotemporal dementia, or parkinsonism, as well as healthy controls underwent a 60- to 90-minute brain PET scan after 7 mci (259 MBq) injection of F-PI-2620. Some participants had previous PET scans using F-THK-5351 or F-FP-CIT for dopamine transporter imaging. RESULTS: All participants showed no increase in off-target binding in basal ganglia on F-PI-2620 PET images, as noted for first-generation tau tracers. Aβ+ mild cognitive impairment or AD patients showed diverse cortical F-PI-2620 uptake in frontotemporoparietal cortex that correlated with Mini-Mental Status Examination (ρ = -0.692, P = 0.013). Aβ+ Parkinson disease with dementia and (Aβ unknown) primary progressive aphasia patients also showed increased F-PI-2620 uptakes in the frontotemporoparietal cortex. Patients with parkinsonism showed increased uptakes in the pallidum compared with Aβ- healthy controls (left: 1.41 ± 0.14 vs 1.04 ± 0.13, P = 0.014; right: 1.18 ± 0.16 vs 0.95 ± 0.07, P = 0.014). CONCLUSIONS: F-PI-2620 PET might be a sensitive tool to detect cortical tau deposits in patients with Aβ+ AD and Aβ+ non-AD tauopathies. Furthermore, this study showed that "off-target" binding in the basal ganglia does not affect F-PI-2620.
引用
- Oh M, Oh SJ, Lee SJ, et al. Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351. Clin Nucl Med. 2020. PMID: 32910050. doi:10.1097/RLU.0000000000003261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。